1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > PharmaPoint: Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2024

Summary

Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer death in the world. The major treatments for G/GEJAC are chemotherapy-based, but targeted therapies such as HER2 and angiogenesis inhibitors have been approved and are being added to chemotherapy regimens since 2010 and 2014, respectively.

GlobalData estimates the 2014 sales for G/GEJAC at approximately $1.13 billion across the 8MM covered in this report. The market is expected to reach $4.39 billion in 2024 at a CAGR of 14.6%. This growth will be mainly driven by the approval and uptake of premium-priced products, such as Eli Lilly’s Cyramza (ramucirumab) and PD-1-targeting mAbs, Merck & Co.’s Keytruda (pembrolizumab) and BMS’ Opdivo (nivolumab). GlobalData expects, by the end of the forecast period, Cyramza to dominate the G/GEJAC market with an overall 37% share of the G/GEJAC market.

The G/GEJAC pipeline is strong; however, GlobalData expects many of these drugs to launch only in Japan and China, limiting their outlook. For the pipeline drugs that are in a global development. Roche’s Perjeta (pertuzumab) and Merck & Co.’s Keytruda are the most promising. While the HER2-positive segment of the G/GEJAC will be dominated by Roche over the forecast period, GlobalData projects there will be opportunities for companies to develop novel therapeutics targeting the HER2-negative first-line setting.

Highlights

Key Questions Answered

- What will be the impact of the new anti-PD-1 inhibitors and their projected label expansions on the G/GEJAC market sales? Given the recent reports on clinical efficacy of these pipeline drugs, there is a good deal of potential in the G/GEJAC space for anti-PD-1 inhibitors over the forecast period.
- As the HER2-positive segment of the G/GEJAC market is dominated by Roche, pharmaceutical companies aim to establish their foothold in the underserved HER2-negative space. What R&D strategies are being pursued by drug makers to stand out?
- The development of drugs for G/GEJAC has been slow, especially after the failure of Phase III trials of multiple pre-2014 pipeline agents. Therefore, there are considerable high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the G/GEJAC market?

Key Findings

- One of the main drivers of the enormous expansion of the G/GEJAC market will be the launch of premium-priced metastatic therapies, such as HER2-targeted therapy Perjeta, and anti-PD-1 immunotherapies Keytruda and Opdivo. The uptake of recently-approved Cyramza and its projected label expansion into the HER2-negative first-line setting will also be key. These drugs will extend treatment duration and will be added onto the current standard-of-care regimens.
- Key patent expiry of Herceptin across the major markets and subsequent biosimilar entries expected starting in 2017 represent a major barrier of the growth of the G/GEJAC market. GlobalData expects trastuzumab biosimilars to occupy a fifth of total molecule sales in 2024, the end of the forecast period.
- Companies are focusing on the development of therapies for the second-line treatment and for HER2-negative patients in the first line, trying to avoid excessive competition with the current standard of care.
- One of the largest unmet needs is efficacious perioperative and postoperative treatment options for resected patients to prevent disease recurrence. Currently, no company-sponsored trials are planed to address this unmet need.

Scope

- Overview of G/GEJAC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized G/GEJAC therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments (including adjuvant, HER2-positive and HER2-negative), forecast from 2014 to 2024.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the G/GEJAC therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidate in Phase III development is profiled.
- Analysis of the current and future market competition in the global G/GEJAC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global G/GEJAC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global G/GEJAC therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table Of Contents

PharmaPoint: Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2024
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 26
2.1 Catalyst 26
2.2 Related Reports 27
2.3 Upcoming Related Reports 27
3 Disease Overview 28
3.1 Etiology and Pathophysiology 28
3.1.1 Etiology 28
3.1.2 Pathophysiology 28
3.1.3 Biomarkers/Targets of Interest 30
3.2 Staging 31
3.3 Symptoms 33
3.4 Prognosis 33
3.5 Quality of Life 34
4 Epidemiology 36
4.1 Disease Background 36
4.2 Risk Factors and Comorbidities 37
4.3 Global Trends 38
4.3.1 8MM, Incidence Trends 39
4.4 Forecast Methodology 41
4.4.1 Sources Used 47
4.4.2 Sources Not Used 55
4.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases of Gastric Cancer - 8MM 56
4.4.4 Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases of Gastric Cancer - 8MM 57
4.4.5 Forecast Assumptions and Methods, Gastric Cancer Clinical Stages at Diagnosis - 8MM 58
4.4.6 Forecast Assumptions and Methods, Gastric Cancer Cellular Types - 8MM 59
4.4.7 Forecast Assumptions and Methods, HER2 Status - 8MM 61
4.4.8 Forecast Assumptions and Methods, Diagnosed Incident Cases of GEJ Cancer - 8MM 62
4.4.9 Forecast Assumptions and Methods, Diagnosed Incident Cases of Gastric Adenocarcinomas - 8MM 64
4.5 Epidemiological Forecast of Gastric Cancer (2014-2024) 64
4.5.1 Diagnosed Incident Cases of Gastric Cancer 64
4.5.2 Age-Specific Diagnosed Incident Cases of Gastric Cancer 66
4.5.3 Sex-Specific Diagnosed Incident Cases of Gastric Cancer 67
4.5.4 Age-Standardized Diagnosed Incidence of Gastric Cancer 69
4.5.5 Percentage Distribution of Diagnosed Incident Cases of Gastric Cancer, by Stage at Diagnosis 70
4.5.6 Percentage Distribution of Diagnosed Incident Cases of Gastric Cancer, by Cellular Type 71
4.5.7 Diagnosed Incident Cases of Gastric Cancer by HER2 Status 72
4.5.8 Diagnosed Incident Cases of GEJ Cancer 74
4.5.9 Five-Year Diagnosed Prevalent Cases of Gastric Cancer 76
4.6 Discussion 77
4.6.1 Epidemiological Forecast Insight 77
4.6.2 Limitations of the Analysis 78
4.6.3 Strengths of the Analysis 79
5 Disease Management 80
5.1 Diagnosis and Treatment Overview 80
5.1.1 Screening 80
5.1.2 Diagnosis 81
5.1.3 Treatment Guidelines and Leading Prescribed Drugs 85
5.1.4 Clinical Practice 85
5.2 US 96
5.2.1 Screening and Diagnosis 97
5.2.2 Clinical Practice 97
5.3 France 99
5.3.1 Screening and Diagnosis 100
5.3.2 Clinical Practice 101
5.4 Germany 101
5.4.1 Screening and Diagnosis 102
5.4.2 Clinical Practice 103
5.5 Italy 104
5.5.1 Screening and Diagnosis 105
5.5.2 Clinical Practice 105
5.6 Spain 106
5.6.1 Screening and Diagnosis 107
5.6.2 Clinical Practice 107
5.7 UK 108
5.7.1 Screening and Diagnosis 109
5.7.2 Clinical Practice 109
5.8 Japan 110
5.8.1 Screening and Diagnosis 111
5.8.2 Clinical Practice 113
5.9 China 118
5.9.1 Screening and Diagnosis 119
5.9.2 Clinical Practice 120
6 Competitive Assessment 125
6.1 Overview 125
6.2 HER2-Targeted Therapy 126
6.2.1 Herceptin (trastuzumab) 126
6.3 Angiogenesis Inhibitors 137
6.3.1 Cyramza (ramucirumab) 137
6.3.2 Aitan (apatinib) 149
6.4 Chemotherapies 155
6.4.1 TS-1 (tegafur, gimeracil, oteracil) 155
6.4.2 Abraxane (nab-paclitaxel) 166
7 Unmet Need and Opportunity 173
7.1 Overview 173
7.2 First-Line Therapy for HER2-Negative Patients 174
7.2.1 Unmet Need 174
7.2.2 Gap Analysis 175
7.2.3 Opportunity 176
7.3 New Molecular Targets for Targeted Therapies 176
7.3.1 Unmet Need 176
7.3.2 Gap Analysis 177
7.3.3 Opportunity 178
7.4 Effective Perioperative and Postoperative Therapies 181
7.4.1 Unmet Need 181
7.4.2 Gap Analysis 182
7.4.3 Opportunity 183
7.5 More Efficacious HER2-Targeted Therapies 184
7.5.1 Unmet Need 184
7.5.2 Gap Analysis 185
7.5.3 Opportunity 186
7.6 Peritoneal Metastases 187
7.6.1 Unmet Need 187
7.6.2 Gap Analysis 188
7.6.3 Opportunity 189
7.7 Better Clinical Trial Design 190
7.7.1 Unmet Need 190
7.7.2 Gap Analysis 190
7.7.3 Opportunity 191
7.8 Early Detection of Gastric and Gastroesophageal Adenocarcinomas 193
7.8.1 Unmet Need 193
7.8.2 Gap Analysis 194
7.8.3 Opportunity 195
8 Pipeline Assessment 196
8.1 Overview 196
8.2 Promising Drugs in Phase III Clinical Development 197
8.3 HER2-Targeted Therapies 198
8.3.1 Kadcyla (T-DM1; trastuzumab emtansine) 198
8.3.2 Perjeta (pertuzumab) 203
8.4 Immune Checkpoint Inhibitors 211
8.4.1 Keytruda (pembrolizumab) 211
8.4.2 Opdivo (nivolumab) 218
8.5 Further Strategies for G/GEJAC Treatment 224
8.5.1 Napabucasin 224
8.5.2 Lynparza (olaparib) 231
8.5.3 Nimotuzumab 239
8.5.4 TAS-118 247
8.6 Early/Near-Phase III Pipeline Drugs 252
8.6.1 GS-5745 252
8.6.2 Masitinib 256
8.7 Promising Drugs in Early-Stage Development 261
8.7.1 Immune Checkpoint Inhibitors 261
8.7.2 MET-Targeting Drugs 263
8.7.3 Antibody-Drug Conjugates 265
8.8 Biosimilars 269
9 Current and Future Players 272
9.1 Overview 272
9.2 Trends in Corporate Strategy 275
9.3 Company Profiles 276
9.3.1 Bristol-Myers Squibb 276
9.3.2 Eli Lilly and Company 279
9.3.3 Merck and Co. 282
9.3.4 Roche 285
9.3.5 Taiho Pharmaceutical 289
9.3.6 Sumitomo Dainippon Pharma 291
10 Market Outlook 294
10.1 Global Markets 294
10.1.1 Forecast 294
10.1.2 Drivers and Barriers - Global Issues 298
10.2 US 301
10.2.1 Forecast 301
10.2.2 Key Events 305
10.2.3 Drivers and Barriers - US 305
10.3 5EU 308
10.3.1 Forecast 308
10.3.2 Key Events 312
10.3.3 Drivers and Barriers - France 312
10.3.4 Drivers and Barriers - Germany 315
10.3.5 Drivers and Barriers - Italy 317
10.3.6 Drivers and Barriers - Spain 319
10.3.7 Drivers and Barriers - UK 321
10.4 Japan 324
10.4.1 Forecast 324
10.4.2 Key Events 328
10.4.3 Drivers and Barriers - Japan 328
10.5 China 331
10.5.1 Forecast 331
10.5.2 Key Events 335
10.5.3 Drivers and Barriers - China 335
11 Appendix 339
11.1 Bibliography 339
11.2 Abbreviations 374
11.3 Methodology 382
11.4 Forecasting Methodology 382
11.4.1 Diagnosed G/GEJAC Patients 382
11.4.2 Percent of Drug-Treated Patients 383
11.4.3 Drugs Included in Each Therapeutic Class 383
11.4.4 Launch and Patent Expiry Dates 384
11.4.5 General Pricing Assumptions 385
11.4.6 Individual Drug Assumptions 387
11.4.7 Generic Erosion 400
11.4.8 Pricing of Pipeline Agents 400
11.5 Primary Research - Key Opinion Leaders Interviewed for this Report 402
11.6 Primary Research - High-Prescriber Survey 405
11.7 About the Authors 406
11.7.1 Analyst 406
11.7.2 Therapy Area Director 406
11.7.3 Epidemiologist 407
11.7.4 Global Head of Healthcare 407
11.8 About GlobalData 408
11.9 Disclaimer 408

1.1 List of Tables
Table 1: Stage Definitions for Gastric Cancer 32
Table 2: Symptoms of Gastric Cancer 33
Table 3: Prognosis of Gastric Cancer in the US and UK 34
Table 4: Risk Factors and Comorbidities for Gastric Cancer 38
Table 5: 8MM, Sources of Gastric Cancer Incidence Data 42
Table 6: 8MM, Sources Used in the Epidemiology Forecast for the Five-Year Diagnosed Prevalent Cases of Gastric Cancer 43
Table 7: 8MM, Sources of Gastric Cancer Stage at Diagnosis According to AJCC, TNM (Tumor, Node, Metastasis) Staging Manual 44
Table 8: 8MM, Sources of Distribution of Gastric Cancer Cases at Diagnosis by Cellular Type 45
Table 9: 8MM, Sources of GEJ Cancer Incidence Data 46
Table 10: 8MM, Sources of HER2-Positive Status in Diagnosed Incident Cases of Gastric Cancer 47
Table 11: 8MM, Diagnosed Incident Cases of Gastric Cancer, Both Sexes, Ages ?20 Years, N, 2014-2024 65
Table 12: 8MM, Age-Specific Diagnosed Incident Cases of Gastric Cancer, Both Sexes, N (Row %), 2014 66
Table 13: 8MM, Sex-Specific Diagnosed Incident Cases of Gastric Cancer, Ages ?20 Years, N (Row %), 2014 68
Table 14: 8MM, Diagnosed Incident Cases of Gastric Cancer, by HER2 Status, Both Sexes, Ages ?20 Years, N (Row %), 2014 73
Table 15: 8MM, Diagnosed Incident Cases of GEJ Cancer, Both Sexes, Ages ?20 Years, N, 2014-2024 75
Table 16: 8MM, Five-Year Diagnosed Prevalent Cases of Gastric Cancer, Both Sexes, Ages ?20 Years, N, 2014-2024 76
Table 17: Clinical Guidelines for Gastric Cancer 85
Table 18: Generic Chemotherapy Regimens Indicated for Gastric Cancer 94
Table 19: Country Profile - US 96
Table 20: Country Profile - France 100
Table 21: Country Profile - Germany 102
Table 22: Country Profile - Italy 104
Table 23: Country Profile - Spain 106
Table 24: Country Profile - UK 108
Table 25: Country Profile - Japan 111
Table 26: Country Profile - China 118
Table 27: Leading Treatments for G/GEJAC, 2015 126
Table 28: Product Profile - Herceptin 127
Table 29: Summary of Results from the ToGA Trial of Herceptin plus FC 132
Table 30: Summary of the Results of the Analysis of the HER2 IHC3+ or IHC2+/FISH+ Subgroup 133
Table 31: Summary of AEs from the ToGA Trial of Herceptin plus FC 134
Table 32: Herceptin SWOT Analysis, 2015 135
Table 33: Global Sales Forecasts ($m) for Herceptin, 2014-2024 136
Table 34: Product Profile - Cyramza 138
Table 35: Summary of the Results from the REGARD of Cyramza 143
Table 36: Summary of the Results from the RAINBOW Trial of Cyramza plus Paclitaxel 144
Table 37: Summary of Trial Results of Cyramza in Combination with mFOLFOX6 in the First-Line Setting 145
Table 38: Summary of AEs from the REGARD Trial of Cyramza Monotherapy 146
Table 39: Summary of AEs from the RAINBOW Trial of Cyramza plus Paclitaxel 147
Table 40: Cyramza SWOT Analysis, 2015 148
Table 41: Global Sales Forecasts ($m) for Cyramza, 2014-2024 149
Table 42: Product Profile - Aitan 150
Table 43: Summary of Aitan Trial Results 152
Table 44: Summary of AEs from Phase III Trial of Aitan 153
Table 45: Aitan SWOT Analysis, 2015 154
Table 46: Global Sales Forecasts ($m) for Aitan, 2014-2024 155
Table 47: Product Profile - TS-1 156
Table 48: Summary of the Results of Three Studies of TS-1 Monotherapy 160
Table 49: Summary of the Results from the ACTS-GC Study of TS-1 161
Table 50: Summary of TS-1 in the DIGEST trial 162
Table 51: Summary of AEs from ACTS=GS Trial of TS-1 Adjuvant Treatment 163
Table 52: Summary of AEs from Trial of TS-1 plus Cisplatin 164
Table 53: TS-1 SWOT Analysis, 2015 165
Table 54: Global Sales Forecasts ($m) for TS-1, 2014-2024 166
Table 55: Product Profile - Abraxane 167
Table 56: Summary of Results from a Phase II Trial of Abraxane 170
Table 57: Safety of Abraxane 171
Table 58: Abraxane SWOT Analysis, 2015 171
Table 59: Global Sales Forecasts ($m) for Abraxane, 2014-2024 172
Table 60: Unmet Needs and Opportunities in G/GEJAC 174
Table 61: Product Profile - Kadcyla 199
Table 62: Kadcyla SWOT Analysis, 2015 203
Table 63: Product Profile - Perjeta 204
Table 64: Summary of the Results of the Phase IIa Trial of the Herceptin/Perjeta-CX Combination 207
Table 65: Safety of the Herceptin/Perjeta-CX Combination 208
Table 66: Perjeta SWOT Analysis, 2015 210
Table 67: Global Sales Forecasts ($m) for Perjeta, 2014-2024 211
Table 68: Product Profile - Keytruda 212
Table 69: Summary of the Results of the KEYNOTE-012 Trial of Keytruda 215
Table 70: Keytruda SWOT Analysis, 2015 217
Table 71: Global Sales Forecasts ($m) for Keytruda, 2014-2024 218
Table 72: Product Profile - Opdivo 219
Table 73: Opdivo SWOT Analysis, 2015 223
Table 74: Global Sales Forecasts ($m) for Opdivo, 2014-2024 224
Table 75: Product Profile - Napabucasin 225
Table 76: Summary of the Results from the Phase Ib/II Trial of Napabucasin 228
Table 77: Napabucasin SWOT Analysis, 2015 230
Table 78: Global Sales Forecasts ($m) for Napabucasin, 2014-2024 231
Table 79: Product Profile - Lynparza 232
Table 80: Summary of Results of the Phase II Trial of Lynparza 235
Table 81: Summary of AEs from Phase II Trial of Lynparza 236
Table 82: Lynparza SWOT Analysis, 2015 238
Table 83: Global Sales Forecasts ($m) for Lynparza, 2014-2024 239
Table 84: Product Profile - Nimotuzumab 240
Table 85: Summary of the Results of the Phase II Trial of Nimotuzumab in Unselected Patients 242
Table 86: Summary of the Results of the Subgroup Analysis of Nimotuzumab in EGFR-Positive Patients 243
Table 87: Summary of AEs from the Phase II Trial of Nimotuzumab in Combination with Irinotecan 244
Table 88: Nimotuzumab SWOT Analysis, 2015 246
Table 89: Global Sales Forecasts ($m) for nimotuzumab, 2014-2024 247
Table 90: Product Profile - TAS-118 248
Table 91: TAS-118 SWOT Analysis, 2015 251
Table 92: Global Sales Forecasts ($m) for TAS-118, 2014-2024 252
Table 93: Product Profile - GS-5745 253
Table 94: GS-5745 SWOT Analysis 256
Table 95: Product Profile - Masitinib 257
Table 96: Summary of the Results of the Phase II Trial of the Masitinib-Chemotherapy Combinations 259
Table 97: Summary of AEs from the Phase II Trial of the Masitinib-Chemotherapy Combinations 259
Table 98: Masitinib SWOT Analysis, 2013 260
Table 99: Early-Stage Immune Checkpoint Inhibitors 261
Table 100: Early-Stage MET-Targeting Drugs 264
Table 101: Early-Stage Antibody-Drug-Conjugates 266
Table 102: Marketed or Phase III Trastuzumab Biosimilars 269
Table 103: Key Companies in the G/GEJAC Market in the 8MM, 2014-2024 273
Table 104: BMS' G/GEJAC Portfolio Assessment, 2015 278
Table 105: Eli Lilly's G/GEJAC Portfolio Assessment, 2015 281
Table 106: Merck and Co.'s G/GEJAC Portfolio Assessment, 2015 284
Table 107: Roche's G/GEJAC Portfolio Assessment, 2015 288
Table 108: Taiho's G/GEJAC Portfolio Assessment, 2015 290
Table 109: SDP's G/GEJAC Portfolio Assessment, 2015 292
Table 110: Global Sales Forecast ($m) for G/GEJAC, 2014-2024 296
Table 111: G/GEJAC Market - Drivers and Barriers, 2015 298
Table 112: Sales Forecast ($m) for G/GEJAC in the US, 2014-2024 303
Table 113: Key Events Impacting Sales for G/GEJAC in the US, 2014-2024 305
Table 114: G/GEJAC Market in the US - Drivers and Barriers, 2015 305
Table 115: Sales Forecast ($m) for G/GEJAC in the 5EU, 2014-2024 310
Table 116: Key Events Impacting Sales for G/GEJAC in the 5EU, 2014-2024 312
Table 117: G/GEJAC Market in France - Drivers and Barriers, 2015 312
Table 118: G/GEJAC Market in Germany - Drivers and Barriers, 2015 315
Table 119: G/GEJAC Market in Italy - Drivers and Barriers, 2015 317
Table 120: G/GEJAC Market in Spain - Drivers and Barriers, 2015 319
Table 121: G/GEJAC Market in the UK - Drivers and Barriers, 2015 321
Table 122: Sales Forecast ($m) for Gastric Cancer in Japan, 2014-2024 326
Table 123: Key Events Impacting Sales for Gastric Cancer in Japan, 2014-2024 328
Table 124: Gastric Cancer Market in Japan - Drivers and Barriers, 2015 328
Table 125: Sales Forecast ($m) for G/GEJAC in China, 2014-2024 333
Table 126: Key Events Impacting Sales for G/GEAJC in China, 2014-2024 335
Table 127: G/GEJAC Market in China - Drivers and Barriers, 2015 335
Table 128: Key Launch Dates 384
Table 129: Key Patent Expiries 385
Table 130 Average Body Weight and Surface Area Across the 8MM 386
Table 131: Average Cost of Therapy of Herceptin 388
Table 132: Average Cost of Therapy of Cyramza 389
Table 133: Average Cost of Therapy of TS-1 390
Table 134: Average Cost of Therapy of Abraxane 391
Table 135: High-Prescribing Physicians Surveyed by Country 405

1.2 List of Figures
Figure 1: 8MM, Age-Adjusted Gastric Cancer Incidence (Cases per 100,000 Population), Men, 1998-2007 40
Figure 2: 8MM, Age-Adjusted Gastric Cancer Incidence (Cases per 100,000 Population), Women, 1998-2007 40
Figure 3: 8MM, Diagnosed Incident Cases of Gastric Cancer, Both Sexes, Ages ?20 Years, N, 2014-2024 65
Figure 4: 8MM, Age-Specific Diagnosed Incident Cases of Gastric Cancer, Both Sexes, N, 2014 67
Figure 5: 8MM, Sex-Specific Diagnosed Incident Cases of Gastric Cancer, Ages ?20 Years, 2014 69
Figure 6: 8MM, Age-Standardized Diagnosed Incidence of Gastric Cancer (Cases per 100,000 Population), Ages ?20 Years, by Sex, 2014 70
Figure 7: 8MM, Percentage Distribution of Diagnosed Incident Cases of Gastric Cancer, by Stage at Diagnosis, Both Sexes, Ages ?20 Years 71
Figure 8: 8MM, Percentage Distribution of Diagnosed Incident Cases Gastric Cancer, by Cellular Type, Both Sexes, Ages ?20 Years 72
Figure 9: 8MM, Diagnosed Incident Cases of Gastric Cancer, by HER2 Status, Both Sexes, Ages ?20 Years, %, 2014 74
Figure 10: 8MM, Diagnosed Incident Cases of GEJ Cancer, Both Sexes, Ages ?20 Years, N, 2014-2024 75
Figure 11: 8MM, Five-Year Diagnosed Prevalent Cases of Gastric Cancer, Both Sexes, Ages ?20 Years, N, 2014-2024 77
Figure 12: Treatment Flowchart for Localized Gastric Cancer 86
Figure 13: Treatment Flowchart for Locoregional Gastric cancer 89
Figure 14: Treatment Flowchart for Metastatic Gastric Cancer 95
Figure 15: Herceptin's Development in G/GEJAC 131
Figure 16: Development of Cyramza in G/GEJAC 141
Figure 17: Development of TS-1 in G/GEJAC 160
Figure 18: Development of Abraxane in Gastric Cancer 169
Figure 19: G/GEJAC - Phase III Pipeline, 2015 197
Figure 20: Competitive Assessment of Late-Stage Pipeline Agents in G/GEJAC, 2014-2024 198
Figure 21: Kadcyla's Development in G/GEJAC 201
Figure 22: Clinical and Commercial Positioning of Kadcyla 202
Figure 23: Perjeta's Development in G/GEJAC 206
Figure 24: Clinical and Commercial Positioning of Perjeta 209
Figure 25: Keytruda's Development in G/GEJAC 214
Figure 26: Clinical and Commercial Positioning of Keytruda 216
Figure 27: Opdivo's Development in G/GEJAC 221
Figure 28: Clinical and Commercial Positioning of Opdivo 222
Figure 29: Napabucasin 's Development in G/GEJAC 227
Figure 30: Clinical and Commercial Positioning of Napabucasin 229
Figure 31: Lynparza's Development in G/GEJAC 234
Figure 32: Clinical and Commercial Positioning of Lynparza 237
Figure 33: Nimotuzumab's Development in Gastric Cancer 241
Figure 34: Clinical and Commercial Positioning of Nimotuzumab 245
Figure 35: TAS-118's Development in Gastric Cancer 249
Figure 36: Clinical and Commercial Positioning of TAS-118 250
Figure 37: GS-5745 's Development in G/GEJAC 254
Figure 38: Clinical and Commercial Positioning of GS-5745 255
Figure 39: Clinical and Commercial Positioning of masitinib 260
Figure 40: Global Sales of Branded Products for G/GEJAC by Company, 2014-2024 274
Figure 41: Company Portfolio Gap Analysis in G/GEJAC, 2014-2024 275
Figure 42: Bristol-Myers Squibb SWOT Analysis in G/GEJAC, 2014-2024 279
Figure 43: Eli Lilly SWOT Analysis in G/GEJAC, 2014-2024 282
Figure 44: Merck and Co. SWOT Analysis in G/GEJAC, 2014-2024 285
Figure 45: Roche SWOT Analysis in G/GEJAC, 2014-2024 288
Figure 46: Taiho SWOT Analysis in G/GEJAC, 2014-2024 291
Figure 47: Sumitomo Dainippon SWOT Analysis in G/GEJAC, 2014-2024 293
Figure 48: Global Sales for G/GEJAC by Region, 2014-2024 297
Figure 49: Sales for G/GEJAC in the US by Drug Class, 2014-2024 304
Figure 50: Sales for G/GEJAC in the 5EU by Drug Class, 2014-2024 311
Figure 51: Sales for Gastric Cancer in Japan by Drug Class, 2014-2024 327
Figure 52: Sales for G/GEJAC in China by Drug Class, 2014-2024 334

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025 Summary Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.